Previous close | 14.80 |
Open | 15.50 |
Bid | 14.60 |
Ask | 15.45 |
Strike | 155.00 |
Expiry date | 2025-01-17 |
Day's range | 14.80 - 15.50 |
Contract range | N/A |
Volume | |
Open interest | 73 |
AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
AbbVie Inc. ( NYSE:ABBV ) shareholders have seen the share price descend 13% over the month. But don't let that...
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.